Enabling innovation for a better world

BioMarin Pharmaceutical Inc, a global biotechnology company, announced that an individual in Germany with severe haemophilia A was treated with ROCTAVIAN (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe.

A tumour-busting drug developed at UCL in London, which scientists say could improve the current “dismal outlook” for people with pancreatic cancer, is set to be trialled in patients following U.S regulatory approval.

Episode 9: HeLP-Diabetes: From early-stage social venture to national roll-out

In the ninth episode of this podcast series, Ana Lemmo Charnalia, Senior Business Manager at UCLB, is in conversation with Orla O’Donnell , Divisional Manager at the UCL Div of Biosciences and former Chief Operating Officer of HeLP Digital CIC, a Community Interest Company incorporated in 2015 to commercialise HeLP-Diabetes.

I/O Lab is a programme specifically designed for UCL academics interested in understanding how to assess the potential of their research in a commercialisation context. I/O Lab runs once a year and is delivered over two months (via in-person weekly sessions) by UCL Business together with the UCL Technology Fund.